Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluation of the Safety and Efficacy of Treatment With BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex for Subjects With Facial Rhytides (Forehead Lines, Glabellar Lines, Lateral Canthal Lines)

Next Previous
Trial Profile

Evaluation of the Safety and Efficacy of Treatment With BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex for Subjects With Facial Rhytides (Forehead Lines, Glabellar Lines, Lateral Canthal Lines)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 01 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Botulinum-Toxin-A (Primary)
  • Indications Facial wrinkles; Glabellar lines
  • Focus Registrational; Therapeutic Use
  • Sponsors Allergan

Most Recent Events

  • 30 Aug 2023 According to AbbVie media release, post-hoc analysis data (from two phase 3 studies NCT02261467 and NCT02261493) presented in the Journal of Cosmetic Dermatology.
  • 30 Aug 2023 Results of post hoc analysis (from two phase 3 studies NCT02261467 and NCT02261493) presented in the AbbVie Media Release
  • 18 Dec 2017 Accoridng to a Allergan media release, based on the data of this and other phase III trial (250237), Vistabel (botulinum toxin type A) received a positive opinion from ANSM (France) for the temporary treatment of moderate to severe forehead lines in adult patients in 30 European countries.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top